We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
The Best of the Best |

Top-Accessed Article: Cantharidin Revisited FREE

Amy Yuntzu-Yen Chen, MD; Michael P. Heffernan, MD
Arch Dermatol. 2012;148(4):454. doi:10.1001/archdermatol.2011.1612.
Text Size: A A A
Published online

Moed L, Shwayder TA, Chang MW. Cantharidin revisited: a blistering defense of an ancient medicine. Arch Dermatol. 2001;137(10):1357-1360.

Moed and colleagues present a comprehensive review of cantharidin. They delineate the historical and folk uses of cantharidin as well as governmental regulatory issues. Although cantharidin lost Food and Drug Administration approval in 1962, it has been proposed for inclusion in the “Bulk Substances List” and may be obtained through compounding pharmacies or proprietary sources. The authors outline the mechanism of action of cantharidin and its dermatologic applications. Although topical treatment with cantharidin rarely results in scarring or systemic intoxication, they note that deaths due to ingestion have been reported. The authors also review the symptoms of and treatment for systemic cantharidin poisoning. With this article, Moed and coauthors offer reassurance that proper in-office application of topical cantharidin remains a safe and valuable therapeutic option for warts and molluscum.

From August 2009 through August of 2010, this article was viewed 2036 times on the Archives of Dermatology Web site.


Contact Dr Chen at the Department of Dermatology, Wright State University, Boonshoft School of Medicine, One Elizabeth Place, Ste 200, Dayton, OH 45417 (ayyen@alum.mit.edu).





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Related Content

Customize your page view by dragging & repositioning the boxes below.